M. Mercer

Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.

J. Fozard, T. Keller, David Beer, 2012, Journal of medicinal chemistry.

The discovery of orally available thrombin inhibitors: studies towards the optimisation of CGH1668.

D. Janus, K. Menear, David J. Farr, 1998, Bioorganic & medicinal chemistry letters.

Studies towards the identification of potent, selective and bioavailable thrombin inhibitors.

D. Janus, K. Menear, D. Bentley, 1999, Bioorganic & medicinal chemistry letters.

A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential.

J. Fozard, T. Keller, N. Press, 2005, Bioorganic & medicinal chemistry letters.

The discovery of orally available thrombin inhibitors: optimisation of the P1 pharmacophore.

B. Wathey, D. Janus, K. Menear, 1999, Bioorganic & medicinal chemistry letters.

Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).

T. Keller, David Beer, N. Press, 2015, Journal of medicinal chemistry.

The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.

J. Fozard, S. Charlton, M. Gosling, 2014, Bioorganic & medicinal chemistry letters.